Hybrid PET/CT in Cancer Patients

This study has been completed.
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT00396916
First received: November 7, 2006
Last updated: April 10, 2007
Last verified: April 2007

November 7, 2006
April 10, 2007
December 2004
Not Provided
the impact of the imaging modality on patient management
Same as current
Complete list of historical versions of study NCT00396916 on ClinicalTrials.gov Archive Site
the impact of the imaging modality on patient management
Same as current
Not Provided
Not Provided
 
Hybrid PET/CT in Cancer Patients
The Value of Novel Imaging Modality, Hybrid PET/CT, Using F18-Flurodeoxyglucose(FDG) in the Assessment of Cancer Patients. Impact of PET/CT on Clinical Management of Patients With Rising Tumor Markers and no Other Evidence of Disease and in Patients With Metastatic Cancer of Unknown Origin

The purpose of the present study is to assess the role of hybrid PET/CT imaging diagnosis of active malignancy in cancer patients with rising tumor markers after treatment and in the diagnosis of primary tumor in patients with metastatic cancer of unknown origin. The clinical impact of PET/CT in the management and treatment of these two groups of cancer patients will be evaluated

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Cancer
Device: PET/CT imaging
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
45
Not Provided
Not Provided

Inclusion Criteria:

  • Cancer patients in complete remission after treatment, with serial elevation of serum tumor markers and negative CT or other conventional imaging test.
  • Patients with newly diagnosed metastatic cancer with unknown primary tumor
  • Glucose levels below 150-200
  • Patient signed informed consent

Exclusion Criteria:

  • Pregnant or lactating women
  • Patient unable or not willing to tolerate the test until its completion
  • One or more of the inclusion criteria is not fulfilled
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00396916
hybridCTIL
Not Provided
Not Provided
Rambam Health Care Campus
Not Provided
Principal Investigator: Rachel Bar-Shalom, MD Rambam Health Care Campus
Rambam Health Care Campus
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP